Alopecia areata associated with abacavir therapy.Abacavir is a nucleoside reverse-transcriptase inhibitor that has been approved for use in combination with other retroviral agents in the treatment of HIV infection.  A fatal hypersensitivity reaction may occur in 5% of patients receiving abacavir; therefore, screening for HLA-B5701 should be performed before starting abacavir.  At present, the occurrence of AA has not been associated with abacavir use.  We cannot exclude that the use of abacavir and the development of AA could be coincidental.  Nevertheless, patients given abacavir should be monitored for hair loss and the drug discontinued promptly if such signs appear.
abacavir
Alopecia areata associated with abacavir therapy.Abacavir is a nucleoside reverse-transcriptase inhibitor that has been approved for use in combination with other retroviral agents in the treatment of HIV infection.  A fatal hypersensitivity reaction may occur in 5% of patients receiving abacavir; therefore, screening for HLA-B5701 should be performed before starting abacavir.  At present, the occurrence of AA has not been associated with abacavir use.  We cannot exclude that the use of abacavir and the development of AA could be coincidental.  Nevertheless, patients given abacavir should be monitored for hair loss and the drug discontinued promptly if such signs appear.
abacavir
Alopecia areata associated with abacavir therapy.Abacavir is a nucleoside reverse-transcriptase inhibitor that has been approved for use in combination with other retroviral agents in the treatment of HIV infection.  A fatal hypersensitivity reaction may occur in 5% of patients receiving abacavir; therefore, screening for HLA-B5701 should be performed before starting abacavir.  At present, the occurrence of AA has not been associated with abacavir use.  We cannot exclude that the use of abacavir and the development of AA could be coincidental.  Nevertheless, patients given abacavir should be monitored for hair loss and the drug discontinued promptly if such signs appear.
abacavir
Alopecia areata associated with abacavir therapy.Abacavir is a nucleoside reverse-transcriptase inhibitor that has been approved for use in combination with other retroviral agents in the treatment of HIV infection.  A fatal hypersensitivity reaction may occur in 5% of patients receiving abacavir; therefore, screening for HLA-B5701 should be performed before starting abacavir.  At present, the occurrence of AA has not been associated with abacavir use.  We cannot exclude that the use of abacavir and the development of AA could be coincidental.  Nevertheless, patients given abacavir should be monitored for hair loss and the drug discontinued promptly if such signs appear.
abacavir